Sweden's ChemoTech Q4 sales rise on Animal Care unit strength

Scandinavian ChemoTech AB

17/02/2026 07:39

Overview

Swedish medical tech firm's Q4 net sales rose yr/yr, driven by Animal Care segment

Q4 operating cash flow improved significantly compared to last year

Company reports strong Animal Care sales and first U.S. order from equine clinic

Outlook

ChemoTech plans initial technical tests for next-gen vetIQure platform in 2026

Company sees North America as key market opportunity for growth

ChemoTech aims to strengthen presence in Europe as market conditions evolve

Result Drivers

ANIMAL CARE SALES - Strong Q4 sales in Animal Care segment exceeded expectations despite anticipated seasonal slowdown

U.S. MARKET ENTRY - First U.S. order from leading equine clinic in Kentucky marks significant market entry

TREATMENT KIT SALES - Cumulative number of treatment kits sold more than doubled from 2024, driven by higher utilization and confidence

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 2.65 mln
Q4 EPS
-SEK 0.10
Q4 Operating Cash Flow
-SEK 338,000


Analyst Coverage

Wall Street's median 12-month price target for Scandinavian ChemoTech AB is SEK6.30, about 67.6% above its February 16 closing price of SEK3.76

Press Release: ID:nWkr1q9DYr

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)